Author: [none given]
RXi Pharmaceuticals Corporation, a RNAi-based therapeutic discovery and development company, has received an advanced technology small business innovation research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). All the participants are based in the US.
The grant will provide funding for pre-clinical development of RNAi therapeutics using RXi's novel, proprietary therapeutic platform, which includes both novel RNAi compounds and advanced delivery technologies.
RXi received approximately $0.3 million per year for this two-year phase I grant with the first year being awarded for 2010, and the second year for 2011 subject to customary conditions. Additional funding of up to $1 million per year over a time period of up to three years may be requested for phase II.
Deal Value (US$ Million) 1.6 Deal Type Partnership Sub-Category Other Deal Status Announced: 2010-07-13
Deal Participants
Partner 1 (Company) National Institute of Allergy and Infectious Diseases Partner 2 (Company) RXi Pharmaceuticals Corporation
For full details on RXi Pharmaceuticals Corporation (RXII) RXII. RXi Pharmaceuticals Corporation (RXII) has Short Term PowerRatings at TradingMarkets. Details on RXi Pharmaceuticals Corporation (RXII) Short Term PowerRatings is available at This Link.
Trading Markets,